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Abstract
Purpose: To investigate dosimetric effects of bladder distention on organs at risk (OARs) during treatment of endo-
metrial cancer using 3D image-based planning of postoperative vaginal vault brachytherapy (BRT).
Material and methods: Fifteen patients with early-stage endometrial cancer were studied, each undergoing adju-
vant BRT of vaginal vault via 3.5 cm diameter cylinder. As treatment, 25 Gy in 5 fractions were delivered to 5 mm depth 
of the vaginal mucosa. Dose-volume histograms of OARs were generated individually with bladder empty and with 
bladder inflated by sterile saline (180 ml), to compare doses received.
Results: Bladder distention appreciably impacted dosimetry of bladder, sigmoid colon, and small bowel, but do-
simetry of rectum was unaffected. With bladder inflated, mean cylinder-to-bowel distance increased significantly 
(1.69 cm vs. 1.20 cm; p = 0.006). Mean minimum dose to most exposed 2 cc (D2cc) volume also rose significantly at blad-
der (5.40 Gy vs. 4.55 Gy [18.7%]; p < 0.001), as opposed to near-significant reductions in D2cc at sigmoid colon (15.1%; 
p = 0.11) and at small bowel (10.5%; p = 0.14). A full bladder had no effect on dose to 50% volume (D50%) of bladder 
or rectum, and declines seen in mean D50% values of sigmoid colon (22.7%; p = 0.12) and small bowel (19.0%; p = 0.13) 
again fell short of statistical significance.
Conclusions: The combination of a full bladder and an empty rectum may cause significant unwanted increases 
in BRT dosing of bladder, without significantly impacting sigmoid colon and small bowel exposures. These findings 
should be validated through further clinical studies.
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Purpose
Endometrial cancer is the most common gynecologic 
malignancy and is largely diagnosed in early stages [1,2]. 
The primary means of treating localized disease is total 
abdominal hysterectomy and bilateral salpingo-oopho-
rectomy. For all but low-risk tumors, adjuvant radiother-
apy (RT) is thought to reduce chances of loco-regional 
relapse [3], which develops in 10-15% of patients with 
early-stage disease (chiefly as vaginal vault recurrence). 
Adjuvant treatment generally consists of either external 
beam RT (ERBT) or internal brachytherapy (BRT) [3]. In 
recent studies, especially in early stage endometrial carci-
noma, EBRT has shown no advantage over BRT, and EBRT 
carries a greater risk of complications [4]. The PORTEC-II 
(Postoperative Radiation Therapy for Endometrial Carci-
noma) study, a randomized trial of adjuvant RT for en-
dometrial cancer, confirmed that vaginal BRT is effective 
and does not decrease quality of life as much as EBRT, 
leading to an upsurge in the use of high dose rate (HDR) 
vaginal vault BRT [3-5]. In the PORTEC-II trial compared 
with EBRT, reports of toxicity due to vaginal vault BRT 
are fewer, although currently does indicate a 12.6% rate 
of Grade 1 and 2 gastrointestinal side effects with some 
Grade 3 events (< 1%) emerging as late complications [5].
Most of the data published lately on vaginal vault BRT 
stem from 2D plain film-derived conventional plans. The 
chief drawback of this approach is that doses to adjacent 
organs, mainly rectum and bladder, may be inadequately 
assessed. With the advent of computed tomography (CT)-
based conformal plans, prescribed doses to target vol-
umes and collateral exposure to bladder and rectum are 
clearly identified [6,7]. However, the International Com-
mission on Radiation Units and Measurements (ICRU) 
defines only bladder and rectal reference points in 2D 
plans, which may not represent actual 3D dose distribu-
tions. Even more worrisome is the fact that doses to small 
bowel are simply ignored in conventional BRT plans, de-
spite the close proximity of vaginal cylinder.
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Many studies have evaluated the use of CT-based 
conformal plans in patients with cervical and endometrial 
cancers [6-9], although dosimetric parameters of 2D and 
3D BRT plans were being compared. The GEC- ESTRO 
Brachytherapy Working Group has recommended con-
touring guidelines, concepts, and terms in three-dimen-
sional magnetic resonance image-based treatment plan-
ning in cervical cancer BRT, with reports confirming 
the safety, feasibility, definite advantages, clinical out-
come, and late toxicities [10,11]. The impact of bladder 
filling on dose distribution has likewise been amply 
studied in the context of cervical cancer and endometri-
um cancer, with conflicting results [9,12-15]. Still, Hung 
et al. [16] have made a formal claim that bladder disten-
tion reduces BRT dose to small bowel in patients with en-
dometrial cancer. Kobzda et al. [15] found that the dose to 
the empty bladder was lower than when the bladder was 
full, and the doses to the bowels increased proportionally 
in the empty state of the bladder comparing to the full 
organ. Despite the abundance of data on bladder disten-
tion during BRT with the uterus intact, BRT delivery via 
vaginal cylinder is seldom a focus of 3D image-based do-
simetric studies.
The purpose of this study was to investigate the do-
simetric effects of bladder distention on organs at risk 
(OARs) during treatment of endometrial cancer (i.e., 
bladder, rectum, sigmoid colon, and small bowel) using 
3D image-based planning of postoperative HDR vaginal 
vault BRT.
Material and methods
Patients
Between November 2013 and January 2014, a total 
of 15 consecutive patients with early-stage endometrial 
cancer were recruited for study, each of whom submit-
ted to postoperative adjuvant BRT of vaginal vault. All 
had undergone total abdominal hysterectomy, and none 
had received EBRT prior to BRT. Approval was obtained 
from the institutional review board for this outcome 
analysis.
Before delivery of BRT, a detailed gynecologic exa-
mination was performed to evaluate vaginal vault and 
to determine applicator diameter. A laxative or enema 
purge of intestinal contents was also required in ad-
vance. Intracavitary BRT was achieved by using plastic, 
CT-compatible applicators to position standard 3.5 cm 
diameter cylinders. After insertion of cylinder to the top 
of the vagina, the applicator was fixed with a universal 
applicator clamping device (Varian Medical Systems, Inc., 
Palo Alto, CA, USA), which was underneath the patient. 
The length of the cylinder protruding outside the vagina 
was noted to ensure accurate repositioning for subsequent 
insertions. The same applicators were utilized throughout 
the course of treatment. Additionally, before each BRT 
sessions, the applicator was checked with fluoroscopy 
whether it was at the same position as the first application. 
A CT scan with 2.5 mm slice thickness through the pelvis 
was carried out at the first BRT application in line with 
departmental policy.
Treatment planning
Prior to BRT, a Foley catheter was inserted, with 7 ml 
of contrast material filling the balloon. Two CT scans were 
then performed following BRT, leaving in place the se-
cured vaginal cylinder applicator. The initial CT scan was 
done with an empty bladder, thereafter infusing sterile 
saline (180 ml) via catheter. A metal clamp was placed to 
prevent voiding, and second CT scan was done with the 
bladder full. The pelvis was scanned from lumbosacral 
junction to ischial tuberosity at 2.5 cm slice thickness. All 
CT slices were ultimately transferred to the 3D treatment 
planning system (BrachyVision™ Eclipse; Varian Medical 
Systems, Palo Alto, CA, USA).
The dose was prescribed to 5 mm depth for the cranial 
3 to 5 cm of the vagina, and the dose delivered during the 
treatment was 25 Gy in 5 fractions. Vaginal length was 
measured on CT images, and two-thirds of the vaginal 
cylinder was routinely activated, in accordance with our 
institutional protocol.
Organs at risk
Bladder, rectum, sigmoid colon, and small bowel 
constituted OARs. In each axial CT slice, external pelvic 
contours of bladder (empty or full), rectum, sigmoid co-
lon, and small bowel were delineated by the treatment 
planning system, using sagittal and coronal views to 
supplement. Oral or intravenous contrast was not used 
during planning CT. Rectum was defined as the colonic 
segment between rectosigmoid junction and anal verge 
[17]. The length of bowel extending proximal to rectum 
and delimited by a transition to vertical orientation was 
considered sigmoid colon. Small bowel encompassed the 
remaining individual intestinal loops, up to the level of 
the inferior sacroiliac joints (excluding rectum and sig-
moid colon), as was previously defined [12]. To ensure 
structural consistency of patient scan sets (with bladder 
empty and full), contours of rectum, sigmoid colon, and 
small bowel were examined in corresponding CT slices 
to verify that bony landmarks and axial sections of or-
gans closely matched.
For assessment of the distance between the cylinder 
applicator and bowel, the cylinder-to-bowel distance was 
defined as the shortest distance from the cylinder apex 
to the contoured sigmoid or small bowel. Distances were 
measured by use of the sagittal slice through the mid-
plane of the cylinder, by a single investigator to minimize 
the risk of interobserver variation.
Statistical analysis
Statistical analysis relied on standard software (SPSS 
v20.0; SPSS Inc., Chicago, IL, USA). Volumes of all OARs 
specified were determined, and dose-volume histograms 
generated in each bladder state were compared. Volume 
dose values were expressed as minimum doses to most ex-
posed 0.1-, 0.2-, 0.5-, 1.0-, and 2.0-cc volumes (D0.1cc to D2cc) 
and dose received by 50% of OAR volume (D50%). In addi-
tion, OAR dosing minimum (Dmin), maximum (Dmax), mean 
(Dmean), and median (Dmedian) values were calculated for 
both plans. The Wilcoxon matched-pairs test was applied to 
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identify statistical differences in volumes and doses of empty 
and full bladder states. The Mann-Whitney U test was also 
engaged to compare volumes or dose values in independent 
patient groups. All p values were two-sided, with statistical 
significance set at p < 0.05.
Results
Median age of the 15 patients analyzed was 58 years 
(range, 38-81 years). Eight patients (53%) had stage IA en-
dometrial cancer, and seven patients (47%) had stage IB 
disease. As demonstrated in Table 1, all target and OAR 
volumes (except bladder) were similar. Typically, small 
bowel was displaced anteriorly and superiorly from the 
vaginal cylinder applicator (shown in Fig. 1), significantly 
Fig. 1. Organs at risk (OARs) in axial plane with bladder empty (A) and full (B) (small bowel displaced by vaginal cylinder 
applicator); Vaginal cylinder (relative to OARs) in sagittal plane with bladder empty (C) and full (D) (small bowel displaced 
anteriorly and superiorly but stable posteriorly)
Table 1. Target volume and organ-at-risk volumes in 
full and empty bladder plans
Volume Empty bladder  
(cc ± SD)
Full bladder  
(cc ± SD)
p
CTV 99.4 ± 21.5 100.4 ± 22.3 0.27
Rectum 81.3 ± 31.7 83.9 ± 39.1 0.31
Bladder 55.0 ± 14.4 255.1 ± 32.3 < 0.001
Sigmoid 59.9 ± 29.7 63.5 ± 30.2 0.76
Intestine 348.5 ± 107.6 337.9 ± 104.6 0.27
CTV – clinical target volume
A
C
B
D
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increasing mean cylinder-to bowel distance (1.69 cm vs. 
1.20 cm; p = 0.006).
Bladder distention had no impact on dosimetry of rec-
tum (Fig. 2A). However, the effects on bladder (Fig. 2B), 
sigmoid colon (Fig. 2C), and small bowel (Fig. 2D) dosim-
etry were appreciable. With a full bladder, mean D2cc of 
bladder significantly increased from 4.55 Gy to 5.40 Gy 
(18.7% gain; p < 0.001), and reductions in mean D2cc val-
ues of sigmoid colon (15.1%) and small bowel (10.5%) 
neared statistical significance (Table 2).
D50% values of rectum and bladder were unaffect-
ed by bladder distention (Table 3), and declines seen in 
mean D50% values of sigmoid colon (22.7%, p = 0.12) and 
small bowel (19.0%, p = 0.13) again fell short of statistical 
significance.
Discussion
In this study, we determined that the combination of 
a distended bladder and an empty rectum prior to BRT 
significantly increases bladder doses, with decreases in 
sigmoid colon and small bowel exposures that neared 
statistical significance and no impact on rectal dosimetry.
Based on PORTEC-II study outcomes, adjuvant vag-
inal vault BRT has been accepted as standard therapy in 
early-stage endometrial cancer. Unfortunately, earlier 
methods of BRT planning involved orthogonal films, re-
stricting doses to a 5 mm distance from cylinder. In ad-
dition, doses to rectum and bladder were perhaps inac-
curately gauged by ICRU reference points. Although the 
chief toxicities for vaginal cuff BRT are appropriate to be 
intestinal, due to close proximity of the vaginal cylinder, 
conventional plans provide no reference points for defin-
ing doses to small bowel. Hence, determining OAR expo-
sures through CT-based planning is of particular interest.
CT-based plans have been routinely used in cervical 
cancer BRT, where target volumes are managed with 
comparatively greater sophistication. A US survey indi-
cates that most centers do not routinely document OAR 
doses during adjuvant vaginal cuff BRT after hysterec-
tomy [3]. Holloway et al. [18] investigated the need for 
CT-based treatment planning on each insertion of vaginal 
vault BRT, and found that doses to adjacent organs did 
not vary significantly between fractions. Nevertheless, an 
awareness of collateral exposures is needed to ensure that 
side effects of such therapy, given as prophylactic treat-
ment, are not excessive.
In order to reduce OAR doses, the impact of blad-
der distention has been investigated. Results of this stra-
tegy in patients with cervical cancer have conflicted, 
most reporting marginal differences in dosing decre-
ments [12-14]. Few researchers have examined the im-
pact of bladder distention on dose to OARs in patients 
treated post-hysterectomy with HDR vaginal cuff BRT 
[15,16,19,20]. Hoskin and Vidler [19] found that 100 ml 
bladder infusions reduced exposure of small bowel with-
in the high-dose treatment region (as measured on CT 
slices through cranial-most dwell positions) by 57.5%, 
compared with a voided bladder. At the same time, 
mean maximal bladder dose did not change significantly. 
Of note, values were based on 2D measurements of blad-
der height; thus, volumetric parameters of bladder were 
not assessed, and doses to sigmoid colon and small bow-
el were not evaluated. Kobzda et al. [15] found the dose to 
Fig. 2. Dose-volume histograms with bladder empty (dashed line) and full (red line): (A) rectum, (B) bladder, (C) sigmoid colon, 
and (D) small bowel
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the empty bladder is lower than when the bladder is full 
(4.6 Gy (range: 3.1-5.6 Gy) vs. 4.9 Gy (range: 3.9-5.9 Gy); 
p < 0.05), and the doses to the bowels increase propor-
tionally in the empty state of the bladder comparing 
to the full organ (4.6 Gy (range: 2.5-7.3 Gy) vs. 4.1 Gy 
(range: 1.3-5.7 Gy); p < 0.05).
When Stewart et al. [20] examined the effects of blad-
der distention on BRT doses to bladder, rectum, and 
urethra using 3D image-based treatment planning, they 
found a correlation between midline maximal bladder 
point dose and maximal rectal point dose. Their conclu-
sion was that maximal bladder point and maximal rectal 
point were acceptable surrogates of D2cc volumetric as-
sessment. Similar to our findings, Stewart et al. [20] report-
ed that bladder distention increased the D2cc of bladder, 
with no appreciable change in D2cc of rectum. Dosimetry 
of sigmoid colon and small bowel, were not evaluated, 
but they too documented a significant increase in cylin-
der-to-bowel distance (0.57 cm to 1.16 cm; p = 0.002) with 
filling of the bladder. In our study, cylinder-to-bowel dis-
tance increased from 1.20 cm to 1.69 cm (p = 0.006).
Hung et al. [16] also evaluated OAR doses to rectum, 
bladder, sigmoid colon, and small bowel. As reported, 
a full bladder resulted in a significant reduction in mean 
D2cc of small bowel (677 to 408 cGy; –39.7%) and D50% of 
small bowel (168 to 132 cGy; –21.4%). Corresponding D2cc 
and D50% doses to rectum and to sigmoid colon were un-
affected by bladder distention. Our detailed dosimetric 
assessment was at odds with these findings, showing in-
stead that bladder distention significantly increases doses 
to bladder, whereas sigmoid colon and small bowel expo-
sures declined to near significant levels.
Above differences may be attributed to the inherent 
uncertainties in measuring exceedingly small distances 
of select regions in mid-sagittal imaging plane. Variance 
in full bladder volumes between studies also may have 
contributed to disparities. In the study conducted by 
Stewart et al. [20], a full bladder was defined as the vol-
ume achieved by a 32 oz intake of water 1 hour prior to 
cylinder insertion. Similarly, Kobzda et al. [15] provided 
a sufficient bladder filling by asking to consume 400 ml 
of water 40 minutes before the CT scans were taken. On 
the other hand, Hung et al. [16] defined a full bladder as 
a 180 ml infusion of sterile water.
We performed two CT scans, one with the bladder 
emptied by Foley catheter, and one following retrograde 
infusion of saline (180 ml) via Foley catheter. Mean full 
bladder volumes of 32 US fl oz (946 ml) for Stewart et al. 
[20], 235.0 ml for Hung et al. [16], 229.7 ml for Kobzda 
et al. [15], and 255.1 ml in the current study were sub-
sequently recorded. Another reason of having larger 
bladder volume in Stewart et al. and our study is, in both 
studies urinary catheter was used to inflate bladder, com-
pared to other studies. A larger bladder expanse may 
displace small bowel to a greater extent, thus explaining 
the increases in cylinder-to-bowel distance registered by 
Stewart et al. [20] and in our work.
Our dosimetric study has some limitations, primarily, 
the limited number of patients recruited, both of which 
curtail any generalization of results. Furthermore, with-
out standardization of bladder filling it is difficult to is-
sue recommendations for filling of the bladder during 
vaginal vault BRT. However, our study does underscore 
that bladder distention may cause unwanted increases in 
bladder doses, while decreasing doses to sigmoid colon 
and small bowel. Finally, our investigation was a do-
simetric study by design, devoid of clinical outcomes. 
Further clinical investigation with extended follow-up is 
needed to determine its practical merit.
Conclusions
This dosimetric study illustrates that the combina-
tion of a distended bladder and an empty rectum prior 
to BRT of vaginal vault may cause significant increases in 
bladder doses, while possibly lowering doses to sigmoid 
colon and small bowel. Because the impact of bladder 
distention on gastrointestinal and genitourinary toxic-
ities has yet to be demonstrated, a suitable bowel prep 
before each therapeutic session may suffice (especially in 
Table 2. Mean D2cc of organs at risk in empty and full bladder plans
Organs Empty bladder (Gy ± SD) Full bladder (Gy ± SD) % Change p
Rectum 5.51 ± 1.01 5.59 ± 1.01 +0.5 0.61
Bladder 4.55 ± 0.72 5.40 ± 1.22 +18.7 < 0.001
Sigmoid 3.83 ± 2.00 3.25 ± 1.27 –15.1 0.11
Bowel 2.94 ± 1.72 2.63 ± 1.88 –10.5 0.14
Table 3. Mean D50% of organs at risk in empty and full bladder plans
Organs Empty bladder (Gy ± SD) Full bladder (Gy ± SD) % Change p
Rectum 3.51 ± 1.61 3.34 ± 1.85 –4.8 0.33
Bladder 2.92 ± 1.23 3.05 ± 2.28 +4.5 0.69
Sigmoid 1.98 ± 1.53 1.53 ± 0.98 –22.7 0.12
Bowel 1.53 ± 0.64 1.24 ± 0.50 –19.0 0.13
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high-volume patient clinics), with no need to inflate the 
bladder. The core concept here is tentative, requiring fur-
ther dosimetric and clinical corroboration.
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